Dear Colleagues and Partners,

In the last decade nontuberculous mycobacterial pulmonary disease and bronchiectasis have become hot topics.

The diagnosis of pulmonary nontuberculous mycobacterial disease and the decision to treat must incorporate several clinical, microbiological, and radiographic features. Although guidelines have been published to aid the clinician in making such decisions, the available evidence indicates that adherence to established guidelines is poor.

An increase in NTM pulmonary and extrapulmonary morbidity and mortality has been documented worldwide, especially among patients suffering from chronic respiratory diseases, including bronchiectasis, chronic obstructive pulmonary disease (COPD), or cystic fibrosis (CF), as well as among HIV-positive and other immunocompromised patients.

In the 10 years that have elapsed since the last multispecialty society guidelines were published, substantial work has been done by investigators worldwide in an attempt to answer key questions related to the epidemiology, prevention, diagnosis and treatment of NTM pulmonary disease. Despite the increased recognition of this group of microorganisms and the important role they play in chronic, pulmonary infectious disease, there are crucial unanswered questions that remain. A new set of European guidelines has been published and is discussed at the meeting.

The prevalence of bronchiectasis in the UK rose by 40% between 2004 and 2014, with similar increases noted worldwide. Growing recognition of this disease is multifactorial, including through greater use of CT scanning, augmented awareness among clinicians, and the documented overlap between bronchiectasis, asthma, and chronic obstructive pulmonary disease (COPD). The increasing burden of bronchiectasis on health-care systems led to a surge in clinical research, new randomized trials, and global growth in specialist services. In September 2017, the European Respiratory Society published guidelines for adult bronchiectasis, which represent the first international standards of care for the disease following several national guidelines produced in the past decade. These guidelines show how far we still are from being able to deliver effective treatment in bronchiectasis.

Registries enrolling large numbers of patients are now reporting on patients from the United States and Europe and we have some insight into the disease in China as well. Our understanding of the microbiology of bronchiectasis is improving and important data have been published on the vicious cycle that relates inflammation and infection. New data on patients’ quality of life and severity assessment are discussed.

The role of macrolide and inhaled antibiotic therapies have been refined and the potential for new anti-inflammatory treatments are emerging.

Finally, collaborations between investigators in many parts of the world have yielded a better definition for a bronchiectasis exacerbation. The evolution of our understanding about this very heterogeneous disease is remarkable but we also await further translational studies and clinical trials to guide the care of individual patients.

There is a clear need for better education and improved knowledge of NTM pulmonary infection and bronchiectasis management.

The 2nd European NTM & Bronchiectasis Workshop gives the opportunity to discuss and analyse the different diagnostic techniques, the role of new drugs and the optimal management of these two important diseases.

Yours Sincerely,

Francesco BLASI
Professor of Respiratory Medicine & Head of the Department of Pathophysiology and Transplantation, University of Milan
Head Internal Medicine Department, Respiratory Unit & Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan
Member of EMBARC (The European Bronchiectasis Network) Steering Committee.
Co-chair of IRIDE (Italian Registry of adult bronchiectasis)
Co-chair of IRENE (Italian Observatory on NTM)
**ORGANISING COMMITTEE**
Stefano ALIBERTI (Italy)
Francesco BLASI (Italy)
James D. CHALMERS (UK)

**SCIENTIFIC COMMITTEE**
J. Stuart ELBORN (UK)
Pieter C. GOEMINNE (Belgium)
Charles S. HAWORTH (UK)
Michael LOEBINGER (UK)
Antoni TORRES (Spain)
Tobias WELTE (Germany)

**VIRTUAL EDITION**
This is a virtual edition of the workshop, including live sessions with Q&A at the end of each lecture

**ORGANISING SECRETARIAT**
PUBLI CREATIONS
74 Bd d’Italie, Monaco
MC, 98000 (Monaco)
Ph: +377 97 97 35 55
ntmbronchiectasis@publiccreations.com

**www.ntmbronchiectasis.org**
<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aliberti Stefano</td>
<td>Italy</td>
</tr>
<tr>
<td>Andrejak Claire</td>
<td>France</td>
</tr>
<tr>
<td>Blasi Francesco</td>
<td>Italy</td>
</tr>
<tr>
<td>Bradley Judy</td>
<td>Ireland</td>
</tr>
<tr>
<td>Carrafiello Gianpaolo</td>
<td>Italy</td>
</tr>
<tr>
<td>Chalmers James D.</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Chang Anne B.</td>
<td>Australia</td>
</tr>
<tr>
<td>Choi Hayoung</td>
<td>South Korea</td>
</tr>
<tr>
<td>Chotirmall Sanjay</td>
<td>Singapore</td>
</tr>
<tr>
<td>Clerici Mario</td>
<td>Italy</td>
</tr>
<tr>
<td>Davies Jane</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Dimakou Katerina</td>
<td>Greece</td>
</tr>
<tr>
<td>Elborn J. Stuart</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Floto Andres</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Flume Patrick</td>
<td>USA</td>
</tr>
<tr>
<td>Goeminne Pieter C.</td>
<td>Belgium</td>
</tr>
<tr>
<td>Gramegna Andrea</td>
<td>Italy</td>
</tr>
<tr>
<td>Greulich Timm</td>
<td>Germany</td>
</tr>
<tr>
<td>Griffith David E.</td>
<td>USA</td>
</tr>
<tr>
<td>Haworth Charles S.</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Loebinger Michael</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Name</td>
<td>Nationality</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Lorent Natalie</td>
<td>Belgium</td>
</tr>
<tr>
<td>Lv Qianting</td>
<td>China</td>
</tr>
<tr>
<td>Martinez Garcia Miguel Angel</td>
<td>Spain</td>
</tr>
<tr>
<td>Morgan Lucy</td>
<td>Australia</td>
</tr>
<tr>
<td>Nolasco Santi</td>
<td>Italy</td>
</tr>
<tr>
<td>Plant Barry</td>
<td>Ireland</td>
</tr>
<tr>
<td>Polverino Eva</td>
<td>Spain</td>
</tr>
<tr>
<td>Ringshausen Felix C.</td>
<td>Germany</td>
</tr>
<tr>
<td>Rohde Gernot</td>
<td>Germany</td>
</tr>
<tr>
<td>Shteinberg Michal</td>
<td>Israel</td>
</tr>
<tr>
<td>Sotgiu Giovanni</td>
<td>Italy</td>
</tr>
<tr>
<td>Tarsia Paolo</td>
<td>Italy</td>
</tr>
<tr>
<td>Tiddens Harm</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Torres Antoni</td>
<td>Spain</td>
</tr>
<tr>
<td>van Ingen Jakko</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Wainwright Claire</td>
<td>Australia</td>
</tr>
<tr>
<td>Welte Tobias</td>
<td>Germany</td>
</tr>
<tr>
<td>Zhang Jimin</td>
<td>USA</td>
</tr>
</tbody>
</table>
This is a virtual edition of the 2nd European NTM & Bronchiectasis Workshop, including LIVE sessions with Q&A at the end of each lecture, fit into the afternoon sessions, which makes the Workshop globally available for everyone.

To access the virtual platform please log on www.ntmbronchiectasis.org
### June 30th, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>MEET THE PROFESSORS’ COURSES</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00 – 13.00</td>
<td>Room 1</td>
</tr>
<tr>
<td></td>
<td>Meet the Professors A</td>
</tr>
<tr>
<td></td>
<td><strong>NTM – PD: Management</strong></td>
</tr>
<tr>
<td></td>
<td><em>M. Loebinger (United Kingdom)</em></td>
</tr>
<tr>
<td>13.00 – 14.00</td>
<td>Room 2</td>
</tr>
<tr>
<td></td>
<td>Meet the Professors C</td>
</tr>
<tr>
<td></td>
<td><strong>NTM &amp; Bronchiectasis in Covid Era – tips and tricks</strong></td>
</tr>
<tr>
<td></td>
<td><em>T. Welte (Germany)</em></td>
</tr>
<tr>
<td>13.00 – 14.00</td>
<td>Room 3</td>
</tr>
<tr>
<td></td>
<td>Meet the Professors D</td>
</tr>
<tr>
<td></td>
<td><strong>Nonpharmacological strategies to mucus clearance</strong></td>
</tr>
<tr>
<td></td>
<td><em>J. Bradley (Ireland)</em></td>
</tr>
</tbody>
</table>
June 30th, 2021

14.00 – 14.10  WELCOME ADDRESS  
Chairs: S. Aliberti (Italy), F. Blasi (Italy), James D. Chalmers (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.10</td>
<td>RISING STAR SESSION</td>
<td>Mepolizumab in severe eosinophilic asthma patients with co-presence of bronchiectasis*</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S. Nolasco (Italy)</td>
</tr>
<tr>
<td>14.25</td>
<td>RISING STAR SESSION</td>
<td>Computer aided analysis of airway-artery dimensions for objective diagnosis and monitoring of bronchiectasis and airway wall thickening in patients with Cystic fibrosis *</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Q. Lv (The Netherlands)</td>
</tr>
<tr>
<td>14.40</td>
<td>RISING STAR SESSION</td>
<td>Questions &amp; Discussion</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Each lecture is followed by 10-minute time for questions and comments as well as advice by the Chairmen.

KEYNOTE LECTURE 1  
Chair: F. Blasi (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.00</td>
<td>Going beyond microbiomes</td>
</tr>
<tr>
<td></td>
<td>S. Chotirmall (Singapore)</td>
</tr>
<tr>
<td>15.20</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

KEYNOTE LECTURE 2  
Chair: A. F.oto (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.30</td>
<td>Nontuberculous mycobacterial pulmonary disease – The new ATS/ERS/ESCMID/IDSA Guidelines</td>
</tr>
<tr>
<td></td>
<td>J. van Ingen (The Netherlands)</td>
</tr>
<tr>
<td>15.50</td>
<td>Discussion</td>
</tr>
</tbody>
</table>

KEYNOTE LECTURE 3  
Chair: C.S. Haworth (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Lecture</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td>Inhaled Amikacin: new data, new studies</td>
</tr>
<tr>
<td></td>
<td>D.E. Griffith (USA)</td>
</tr>
<tr>
<td>16.20</td>
<td>Discussion</td>
</tr>
</tbody>
</table>
July 1st, 2021

**SESSION 1 – BRONCHIECTASIS: WHAT’S NEW?**  
*Chairs: M. A. Martinez Garcia (Spain), K. Dimakou (Greece)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.30 – 12.40</td>
<td>Definition of Bronchiectasis</td>
<td>S. Aliberti (Italy)</td>
</tr>
<tr>
<td>12.40 – 12.55</td>
<td>How to design a real-life clinical trial in bronchiectasis</td>
<td>G. Sotgiu (Italy)</td>
</tr>
<tr>
<td>12.55 – 13.10</td>
<td>Alpha 1 Antitrypsin Genotypes &amp; Bronchiectasis</td>
<td>T. Greulich (Germany)</td>
</tr>
<tr>
<td>13.10 – 13.25</td>
<td>What happened to bronchiectasis during the COVID-19 pandemic?</td>
<td>J. D. Chalmers (United Kingdom)</td>
</tr>
<tr>
<td>13.25 – 13.45</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**KEYNOTE LECTURE 4**  
*Chair: E. Polverino (Spain)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.45 – 14.05</td>
<td>Bronchiectasis exacerbations management</td>
<td>L. Morgan (Australia)</td>
</tr>
<tr>
<td>14.05 – 14.15</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION 2 – TREATING BRONCHIECTASIS BETTER**  
*Chair: C. S. Haworth (UK)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15 – 14.30</td>
<td>Anti-inflammatory drugs – what’s new?</td>
<td>J. S. Elborn (United Kingdom)</td>
</tr>
<tr>
<td>14.30 – 14.45</td>
<td>Antimicrobial Resistance and Antibiotics</td>
<td>P. Flume (USA)</td>
</tr>
<tr>
<td>14.45 – 15.00</td>
<td>Comorbidities in bronchiectasis: do they matter?</td>
<td>E. Polverino (Spain)</td>
</tr>
<tr>
<td>15.00 – 15.15</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**POSTER SESSION – see pages 15-18**  
*Chairs: S. Aliberti (Italy), F. Blasi (Italy), James D. Chalmers (UK)*
July 2nd, 2021

SESSION 3 – NTM TREATMENT
Chair: T. Welte (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
</table>
| 12.30 – 12.45 | MAC-PD: Antibiotics treatment regimens  
M. Loebinger (United Kingdom) |
| 12.45 – 13.00 | NON MAC-PD: Antibiotic treatment regimens  
C. Andrejak (France) |
| 13.00 – 13.15 | Non-antibiotic Treatments  
F. C. Ringshausen (Germany) |
| 13.15 – 13.30 | Discussion |

13.30 – 14.30 SPONSORED SYMPOSIUM – see page 14

SESSION 4 – RADIOLOGY MASTERCLASS
Panel: G. Carrafiello (Italy), A. Gramegna (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.30 – 15.30</td>
<td>Discussion of 3 – 4 clinical cases</td>
</tr>
</tbody>
</table>

SESSION 5 – CYSTIC FIBROSIS: A MODEL FOR AIRWAYS DISEASES?
Chairs: A. Gramegna (Italy), M. Shteinberg (Israel)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
</table>
| 15.30 – 15.45 | From genome to treatment  
J. Davies (United Kingdom) |
| 15.45 – 16.00 | The extrapulmonary effect of CFTR Modulator Therapy  
B. Plant (Ireland) |
| 16.00 – 16.15 | Overview of therapeutics approaches  
J. S. Elborn (United Kingdom) |
| 16.15 – 16.30 | Discussion |
### SESSION 6 – LUNG TRANSPLANT
Chair: F. Blasi (Italy)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13.30–13.45 | Lung transplantation in bronchiectasis and CF: indications and contraindications  
T. Welte (Germany) |
| 13.45–14.00 | Impact of NTM-PD on lung transplantation  
P. Tarsia (Italy) |
| 14.00–14.15 | Discussion |

### BEST ORAL PRESENTATIONS
Chair: A. Torres (Spain), T. Welte (Germany)

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
</table>
| 14.15–14.30 | Characteristics of bronchiectasis in Korea -first data from the KMBARC registry and comparison with other international registries*  
H. Choi (South Korea) |
| 14.30–14.45 | MGIT time-to-positivity is an early biomarker of treatment response in Mycobacterium avium complex pulmonary disease*  
J. van Ingen (The Netherlands) |
| 14.45–15.00 | Neutrophil Serine Protease Levels in Blood and Sputum Samples of Patients on a Reversible Dipeptidyl Peptidase 1 (DPP1) Inhibitor from the WILLOW Phase 2 Trial in Non-Cystic Fibrosis Bronchiectasis*  
J. Zhang (US) |

*Each oral presentation is of 10’ followed by 5’ Questions & Discussion time

### KEYNOTE LECTURE 5
Chair: C. S. Haworth (UK)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15.00–15.20 | NTM-PD: Modifiable risk factors  
A. Floto (UK) |
| 15.20–15.30 | Discussion |

### ABSTRACT AWARD AND CLOSING REMARKS
All the chairs
ON DEMAND KEYNOTE LECTURES

Each lecture will be 30 minutes long with the possibility to ask questions and receive replies from the speakers by e-mail

KEYNOTE LECTURE A

**NTM and Cystic Fibrosis: epidemiology and management of an old enemy**
*C. Wainwright (Australia)*

KEYNOTE LECTURE B

**Machine learning CT in Bronchiectasis**
*H. Tiddens (The Netherlands)*

KEYNOTE LECTURE C

**Lung Immunology: from bench to bedside**
*M. Clerici (Italy)*

KEYNOTE LECTURE D

**Paediatric Bronchiectasis**
*A. Chang (Australia)*
JULY 2\textsuperscript{nd} INDUSTRY SPONSORED SYMPOSIUM

RETHINK NTM: OPTIMISING NTM-PD MANAGEMENT – A PRACTICAL APPROACH  
(sponsored by Insmed)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:30 – 13:35 | **Introduction**  
  *G. Rohde (Germany)* |
| 13:35 – 13:45 | **So we think we know who is at risk of developing NTM-PD – but do we?**  
  *N. Lorent (Belgium)* |
  *C.S. Haworth (United Kingdom)* |
| 13:55 – 14:10 | **Understanding how and when to treat patients once MAC-PD is identified**  
  *S. Aliberti (Italy)* |
| 14:10 – 14:28 | **Panel discussion** |
| 14:28 – 14:30 | **Summary and Close**  
  *G. Rohde (Germany)* |

DISCLAIMER: THE FOLLOWING LECTURES ARE ORGANIZED BY INDUSTRY. YOU CANNOT CLAIM CME CREDITS FOR ATTENDING THIS SESSION.
E-POSTER SESSION

July 1st 15.40 – 17.00

CHAIRS: S. Aliberti (Italy), F. Blasi (Italy), James D. Chalmers (UK)

P. 01 Results of a drug susceptibility study of non-tuberculous mycobacteria isolated from patients with Nontuberculous Mycobacterial Pulmonary Disease

Liudmila Bohush¹

¹Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus

P. 02 Familiar Alpha-1 antitrypsin deficiency (AATD) and increased risk of lung infections due to various Actinomyces.

Paola Francesca Castellotti¹; Sofia Misuraca²; Maurizio Ferrarese¹; Stefania Torri³; Francesco Amati⁴; Luigi Ruffo Codecasa¹

¹Regional Tb Reference Centre, Villa Marelli Institute- ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; ²Department of Pathophysiology and Transplantation, University of Milan, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; ³Regional Tb Reference Lab- ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; ⁴Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

P. 03. Targeting Neutrophilic Inflammation in Bronchiectasis: Design of the Phase 3, Randomized, Double-Blind ASPEN Study Examining Efficacy and Safety of DPP-1 Inhibition

James D. Chalmers¹; Pierre-Régis Burgel²; Charles L. Daley³; Anthony De Soyza⁴; Charles S. Haworth⁵; David T. Mauger⁶; Mark L. Metersky⁷; Kevin C. Mange⁸; Carlos Fernandez⁸; Shande Tang⁸; Zoya Mednikova⁸; Ariel Teper⁸

¹Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, United Kingdom; ²Hôpital Cochin, Respiratory Medicine and Cystic Fibrosis National Reference Center Service de Pneumologie, AP-HP and Université de Paris, Inserm U1016-Institut Cochin, Paris, France; ³National Jewish Health and the University of Colorado, Denver, CO, United States of America; ⁴NIHR Biomedical Research Centre for Aging and Department of Respiratory Medicine, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; ⁵Royal Papworth Hospital NHS Foundation Trust and Department of Medicine, University of Cambridge, Cambridge, United Kingdom; ⁶Department of Public Health Sciences, Pennsylvania State University, Hershey, Hershey, PA, United States of America; ⁷University of Connecticut School of Medicine, Farmington, CT, United States of America; ⁸Insmed Incorporated, Bridgewater, NJ, United States of America
P. 04 The prevalence of eosinophilic bronchiectasis defined by blood and sputum eosinophil counts: an EMBARC analysis

James Chalmers1; Katial Rohit2; Shoemark Amelia1; Jones Martin2; Shtieberg Michael3; Anthony De Soyza4; Peter Goeminne5; Eva Polverino6; Oriol Sibila7; Stefano Aliberti8

1University of Dundee, Nethergate, United Kingdom; 2AstraZeneca, Gaithersburg, United States of America; 3Carmel Medical Center, Haifa, Israel; 4Newcastle University, Tyne, United Kingdom; 5AZ Nikolaas, Sint-Niklaas, Belgium; 6Hospital Vall d’Hebron, Barcelona, Spain; 7Clinic Barcelona, Barcelona, Spain; 8University of Milan, Milan, Italy

P. 05 Mycobacterium chimaera with pulmonary and lymphatic involvement in an immunosuppressed patient: a case report

Francesco Cogliati Dezza1; Giulia Savelloni1; Patrizia Pasculli1; Federica Alessi2; Claudia D’Agostino1; Vito Trinchieri1; Gianluca Russo1; Claudio Maria Mastroianni1

1Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

P. 06 Retrospective analysis of mycobacterial screening in cystic fibrosis patients in a tertiary hospital - rise and relevance of Mycobacterium chelonae

Nico De Crem1; Cindy Ruelens1; Nadia Makki1; Emmanuel André1; Pascal Van Bleyenbergh1; Lieven Dupont1; Natalie Lorent1

1University Hospitals Leuven, Leuven, Belgium

P. 07 Association between bronchiectasis and coronary artery calcium in an Australian cohort

Lewis Holmes1; Paul Lilburn1; Isaac Lui2; Lucy Morgan2,1

1Concord Repatriation General Hospital, NSW, Australia; 2The University of Sydney, NSW, Australia
P. 08 Successful antimycobacterial oral treatment in Mycobacterium abscessus abscessus pulmonary infection during Covid-19 pandemic period: a valid approach based on the molecular and phenotypic sensitivity profile.

M. Libanore¹; D. Campioni²; R. Pora³; A. Bonazza¹; E. Borroni³; A. Barozzi²; L. Romanini²

¹Azienda Ospedaliera Ferrara Infectious Diseases, Ferrara, Italy; ²Azienda Ospedaliera Ferrara Microbiology, Ferrara, Italy; ³San Raffaele-Centre for Tuberculosis, Milano, Italy

P. 09 Medication delivery of bronchiectasis drugs via a breath actuated nebulizer (BAN): Review of delivery performance versus a breath enhanced nebulizer (BEN) commonly used with such medications

Jason Suggett¹; Darlene Haapanen¹

¹Trudell Medical International, London, Canada

P. 10 Clinical characteristics of adult patients with bronchiectasis (Bx) and suspected primary ciliary dyskinesia (PCD) in Ukraine

Kseniia Suska¹; Kateryna Gashynova¹; Valeriia Dmytrychenko¹

¹Dnipro State Medical University, Dnipro, Ukraine

P. 11 Treatment regimen appropriateness for patients enrolled in Italian Registry on Pulmonary Non-Tuberculous Mycobacteria (NTM) - IRENE

Marina Tadolini¹,²; Oscar Braschi¹,²; Vittoria Comellini³; Maura Spotti⁴; Maurizio Ferrarese⁵; Luigi Codecasa⁵; Giovanni Sotgiu⁶; Andrea Gori⁷; Pierluigi Viale¹,²; Francesco Blasi⁷; Stefano Aliberti⁷

¹Division of Infectious Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; ²Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; ³Respiratory and Critical Care Unit, University Hospital St Orsola-Malpighi, Bologna, Italy; ⁴Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milano, Italy; ⁵Regional TB Reference Centre, Villa Marelli Institute/ASST Niguarda, Milano, Italy; ⁶Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; ⁷University of Milan, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano, Milano, Italy
P. 12 Risk factors for non-tuberculous mycobacterial pulmonary disease in France based on health claims database analysis

Roald van der Laan\textsuperscript{1}; Marko Obradovic\textsuperscript{2}; Stephane Bouee\textsuperscript{3}; Camille Nevoret\textsuperscript{3}; Nicolas Veziris\textsuperscript{4}

\textsuperscript{1}Insmed Netherlands BV, Utrecht, Netherlands (The); \textsuperscript{2}Insmed Germany GmbH, Frankfurt, Germany; \textsuperscript{3}CEMKA France, Paris, France; \textsuperscript{4}Sorbonne Université, Centre d’Immunologie et des Maladies Infectieuses (Cimi-Paris), UMR 1135, Département de Bactériologie, Hôpital Saint-Antoine, Centre National de Référence des Mycobactéries, APHP Sorbonne Université, Paris, France

P. 13 Case series: patients with allergic bronchopulmonary aspergillosis (ABPA) treated with dupilumab

Tjeerd van der Veer\textsuperscript{1,2}; Marloes Dallinga\textsuperscript{3}; Menno M van der Eerden\textsuperscript{2}; Gert-Jan Braunstahl\textsuperscript{1,2}

\textsuperscript{1}Franciscus Gasthuis & Vlietland dept. Pulmonology, dept. of Pulmonology, Rotterdam, Netherlands (The); \textsuperscript{2}Erasmus MC, dept. of Pulmonology, Rotterdam, Netherlands (The)
CERTIFICATE OF ATTENDANCE

The certificate of attendance will be downloadable from the website https://www.ntmbronchiectasis.org/ using the personal log-in credentials sent by e-mail, starting from 6th July 2021 and upon having filled the on-line Quality Survey. For Sponsored Groups: Please note that in order to send the certificate of attendance to each participant, we will need the personal e-mail address. The Certificate of attendance will only be delivered to those having attended the Conference.

DIFFERENTIATED ACCESES

Some contents are dedicated to Healthcare Professionals and cannot be accessed by other professionals. Healthcare Professionals and Pharma Company staff members may access all the content of the platform with the exception of the Press Room. Patient Associations Representatives may access all the content of the platform with the exception of promotional contents by Pharma Companies and Press Room. Only Speakers can access the Speakers Ready Room. Only Poster Presenters and Speakers can access the Poster Presenters Ready Room.

EUROPEAN ACCREDITATION

The 2nd European NTM & Bronchiectasis Workshop is granted 10 European CME credits by the European Board for Accreditation in Pneumology (EBAP) and 10 CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®). The Credits Certificate is delivered to those having attended the Conference and having filled the on line Scientific Questionnaire.

To download your certificate please log in to the https://www.ntmbronchiectasis.org/ using the personal log-in credentials sent by e-mail, starting from 6th July, 2021. CME Credits certificates will be downloadable up to 27th July, 2021. After this date, in order to comply with the reporting deadline of UEMS, the CME Credits will no longer be downloadable. For Sponsored Groups: Please note that in order to provide the CME certificate to each participant, we will need their personal e-mail address.
HELP DESK

The secretariat desk will open on Wednesday, 30th June from 11.30 a.m. and will be open as follows:

- 30th of June, Wednesday: 11:30 – 16:30 (CET)
- 01st of July, Thursday: 12:00 – 17:00 (CET)
- 02nd of July, Friday: 12:00 – 16:30 (CET)
- 03rd of July, Saturday: 13:00 – 16:00 (CET)

Contact details are as follows:

**SPEAKERS**

Petra Molnar +36 1 797 3901
Skype: 12ec7f4c71bca221
E – mail: ntmbronchiectasis@publicreations.com

**POSTER PRESENTERS and PARTICIPANTS**

Farkas Gabor +36 1 797 3901
Skype: fgabor16
E – mail: ntmbronchiectasis@publicreations.com

**LANGUAGE**

The official language of the Conference is English. No simultaneous translation is provided.

**LIVE QUESTION CHATS AND LIVE POLL**

The participation to live question chats and live polls during the live sessions is facultative.

**NETWORKING OPPORTUNITIES**

In the Networking Lounge you can see who is connected in each moment, chat with the other participants (general chat of the congress).
Furthermore, accessing the participants list you may download the virtual “Business Card” of other registered participants who have authorised, as yourself, to share their data. The Business Card includes e-mail and phone number to start, eventually, a personal conversation.
PERSONAL DATA AND LIST OF PARTICIPANTS WITH CONTACT

To allow interaction also after the event with other members of the community we invite you, during the registration process, to accept to be included in the list of participants sharing your contacts details.

- Picture (if provided)
- Surname / Name
- Role
- Department
- Institution / Company and address
- Telephone
- Email
- Website

NB: The mobile phone is used only by the secretariat and will not be published. Only in this case you would see the contacts details of other participants who shared this opportunity. At any moment you can access from the platform the page “My Profile” and change the authorization status.

Please note that if you do not provide authorisation to share your data with the other registered participants you cannot access the data of other participants.

PERSONAL CREDENTIALS

To access the 2nd European NTM & Bronchiectasis Workshop use the credential you received when registering and reconfirmed with the confirmation letter received at the end of June. Credentials are strictly personal and you should not share them with colleagues. Free name changes are always possible, please write to ntmbronchiectasis@publiccreations.com. Name changes are guaranteed until 20th June and might not be so immediate during the dates of the live.

Please note that each set of credential provides ONLY ONE ACCESS to the platform.

PRESENCE CONTROL

The virtual platform allows the Congress Secretariat to follow the path done by each participant within the platform.

These data are strictly confidential and is used only for:

- Issue a Certificate of Attendance only to attendees effectively present during the days of the live congress
- Issue CME Credits Certificate to attendees who have effectively followed the sessions

The attendees who have authorised the publication of their data may share them with the relevant sponsor while entering their specific Partner Corporate Page.
POSTER PRESENTERS READY ROOM & POSTERS SESSIONS

Poster Presenters and Speakers can access the Poster Presenter Ready Room starting from 30 minutes before each poster sessions.
Each poster presentation should not exceed 5 minutes.
The best poster will receive the Award for Best Poster Presentation. Winners will be disclosed in the Poster Awards and Closing Remarks on 3rd July at 15.30 (CET).
Poster Award winner will benefit of recognition on the congress website and Official Workshop Book of Abstract, post–congress newsletter, and a free registration for 3rd European NTM & Bronchiectasis Workshop.

SPEAKERS READY ROOM

Only Speakers can access the Speakers Ready Room.
The Speakers Ready Room would be accessible every day from half an hour before the beginning to the end of the live programme. More precisely, the Speakers ready room is available during the following hours:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>30th of June, Wednesday</td>
<td>11:30 – 16:30 (CET)</td>
</tr>
<tr>
<td>01st of July, Thursday</td>
<td>12:00 – 17:00 (CET)</td>
</tr>
<tr>
<td>02nd of July, Friday</td>
<td>12:00 – 16:30 (CET)</td>
</tr>
<tr>
<td>03rd of July, Saturday</td>
<td>13:00 – 16:00 (CET)</td>
</tr>
</tbody>
</table>

Petra Molnár +36 1 797 3901
Skype: 12ec7f4c71bca221
E – mail: ntmbronchiectasis@publiccreations.com

VIRTUAL EVENT

The 2nd European NTM & Bronchiectasis Workshop is realised in virtual format.
The virtual platform is accessible only for registered participants from 30th June, 2021 to 30th December 2021.
As per 13th June, 2021 registered participants may access the:
• Pre-recorded sessions
• Pre-recorded lectures and keynote lecture
• Published Poster Presentations in the Poster Lounge Area
Live sessions as per scientific programme will take place on from 30th June to 3rd July 2021.
Check the programme for timing.
The lives sessions are recorded and made available to all registered participants from 30th June, 2021 to 30th December 2021.
Practical articles
Expert interviews
News and insights

Peer reviewed | Free-to-access | Concise | Multimedia

View | Download | Subscribe FREE

touchRESEARCH.com

Touch Medical Media Services Limited is a private limited company registered in England and Wales with registered number 12930327.
Editorial Boards (selection)

**European**

Dave Singh  
Medicines Evaluation Unit (MEU), University Hospital Of South Manchester NHS Foundation Trust, Manchester, UK

Fabio Midulla  
University of Rome “La Sapienza”, Rome, Italy

Marc Miravitlles  
Chest Physician and Senior Researcher, Department of Pneumology, Hospital Universitari Vall d’Hebron, Barcelona, Spain

Peter Barnes  
National Heart and Lung Institute, Head of Respiratory Medicine, Imperial College, London, UK

Pierre Bartsch  
Medical Clinic VII, Sports Medicine, University Hospital Heidelberg, Heidelberg, German

**US**

Daniel Ouellette  
Wayne State University School of Medicine, Detroit, MI

Harly Greenberg  
North Shore LIJ Sleep Disorders Center, New York, NY

John Davies  
Adult Critical Care at Duke Medical Center, Durham, NC

Juzar Ali  
Wetmore Mycobacterial Disease Program at LSU Health Sciences Center, New Orleans, LA

Paul Williams  
University of Washington, Seattle, WA

Robert Balk  
Division of Pulmonary and Critical Care Medicine and Adult Cystic Fibrosis Program, Rush University Medical Center, Chicago, IL

Terrence Trow  
Pulmonary Vascular Disease Program, Yale University School of Medicine, New Haven, CT

For a full list of experts, visit touchRESPIRATORY.com
Endorsements
Acknowledgements

The Organizing Committee of the 2nd European NTM & Bronchiectasis Workshop would like to express their gratitude to:

MAJOR PARTNER

insmed

SPONSORS

GRIFOLS

Zambon

EDUCATIONAL GRANT

VERTEX

WWW.NTMBRONCHIECTASIS.ORG
A new educational website for health care professionals who manage patients with NTM pulmonary disease (NTM-PD)

Visit www.NTMAction.eu and discover a wealth of content that addresses the management of NTM-PD as well as up-to-date information, useful resources and interactive tools.

Explore sections on:
- Unmet need in NTM-PD
- NTM-PD disease burden
- Who is the patient? Recognising the patient at risk of NTM-PD
- Rationale for treating NTM-PD and how to treat using up-to-date guideline recommendations
- What’s new in NTM-PD? An overview of current NTM publications and clinical trials

- Use the NTM-PD resources – including meetings and webinars with NTM experts, as well as articles exploring all aspects of NTM-PD diagnosis, management and treatment
- Investigate patient profiles
- Test your knowledge with Interactive case studies developed with a panel of experts
- Download educational materials covering the NTM-PD guideline published in 2020¹


www.NTMAction.eu has been developed by Insmed by Insmed. ©2021 Insmed Incorporated all rights reserved. Insmed, the Insmed logo and NTM Action are trademarks of Insmed. Job code: MED-00513